Video

Dr. Yoon on Updated Results of the KEYNOTE-061 Study in Advanced Gastric/GEJ Cancer

Harry H. Yoon, MD, discusses the updated results of the phase 3 KEYNOTE-061 trial in advanced gastric/gastroesophageal junction (GEJ) cancer.

Harry H. Yoon, MD, ​associate professor of oncology, consultant, Division of Medical Oncology, Department of Oncology, co-chair, Esophageal/Gastric Cancer Disease Group, Mayo Clinic, discusses the updated results of the phase 3 KEYNOTE-061 trial in advanced gastric/gastroesophageal junction (GEJ) cancer.

Prior to the KEYNOTE-061 trial, randomized data suggested that nivolumab (Opdivo) was superior to placebo in patients with previously treated advanced gastric/GEJ cancer, says Yoon. However, data also showed that PD-L1 inhibitors did not outperform chemotherapy as third-line treatment. 

The KEYNOTE-061 study randomized previously treated patients with PD-L1–positive advanced gastric/GEJ cancer to receive pembrolizumab (Keytruda) or paclitaxel in the second-line setting, Yoon explains. The long-term findings showed that pembrolizumab elicited a shorter progression-free survival and similar overall survival compared with chemotherapy. 

Further research is needed to determine why the PFS was shorter but the OS was sustained, Yoon concludes. 

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.